Answers are grounded in this paper and cite their sources.
In vitro study demonstrates Airy beam propulsion achieves subcellular drug delivery, promoting cancer cell uptake and apoptosis.
Drug delivery strategies with excellent spatiotemporal controllability and biocompatibility hold exciting prospects in personalized medicine and biopharmaceuticals. Among them, all-optical delivery strategies have attracted significant attention due to their low invasiveness and high positioning accuracy. However, current all-optical schemes predominantly rely on conservative optical gradient force trapping or transient scattering forces propulsion, which cannot sustain stable driving and limit delivery speed. Here, we present an all-optical delivery strategy based on Airy beam, enabling high-speed and subcellular-precision delivery through the synergistic regulation of gradient-scattering forces. The dominant scattering force of Airy beams propels drug carriers at speeds exceeding 400 µm/s, while the gradient force ensures a subcellular delivery precision of ~1 µm during high-speed propulsion. Quantitative measurements using a custom axial imaging module reveal at least a 7-fold speed enhancement over conventional all-optical methods. When applied to anticancer drug delivery, the localized mechanical forces generated by high-speed propulsion enhance stable adhesion of carriers to the cell membrane, thereby promoting drug uptake and accelerating tumor cells apoptosis. This work establishes Airy beams as a powerful tool for drug delivery, opening a new avenue for high-performance all-optical delivery platforms.
No takes yet. Share an insight, caveat, or question.
Qu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: